Drug Profile
Research programme: guanylate cyclase modulators - Bayer/Merck
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Bayer; Merck & Co
- Class
- Mechanism of Action Guanylate cyclase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Pulmonary arterial hypertension; Pulmonary hypertension
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cardiovascular-disorders in Germany
- 28 Jul 2018 No recent reports of development identified for research development in Pulmonary-arterial-hypertension in USA
- 28 Jul 2018 No recent reports of development identified for research development in Pulmonary-hypertension in USA